Pharmadrug Inc Stock Price, News & Analysis

PharmaDrug (OTC: LMLLF) executed a definitive securities exchange agreement to acquire up to a 40% equity interest in Canurta in two tranches via issuance of an aggregate 83,645,316 PHRX shares at the 20‑day VWAP prior to each closing.

The first closing will exchange 8,109,987 Canurta LP units for 25,980,000 PHRX shares on or about Nov 10, 2025. The second closing will exchange 8,191,495 LP units for 57,665,316 PHRX shares on or before Jan 31, 2026, subject to Canadian Securities Exchange and shareholder approval; a shareholder meeting is expected in early Jan 2026.

On completion, Canurta would hold ~44% of PharmaDrug pro forma. The deal includes a recission right expiring by Mar 1, 2026 and forgivable promissory notes of $85,000 at each closing bearing 12% interest to support working capital.

PharmaDrug (OTC:LMLLF) has issued a correction to its July 30, 2025 news release regarding its LOI to acquire equity interest in Canurta Inc. The company clarified that the second tranche will involve 57,665,316 shares (not 32,827,438 as previously stated) and the total share issuance will be 83,645,316 (not 58,807,438).

The corrected deal structure involves PharmaDrug acquiring 40% equity in Canurta through two tranches (19.9% and 20.1%). Upon completion, Canurta will hold approximately 44% of PharmaDrug's shares. The transaction includes $85,000 contributions from Canurta per tranche and the appointment of Canurta's CEO, Akeem Gardner, to PharmaDrug's Board upon first tranche closing.

PharmaDrug (OTC:LMLLF) has signed a non-binding Letter of Intent to acquire up to 40% equity interest in Canurta Limited Partnership, a biotechnology company focused on botanical drugs for inflammation and neurodegenerative diseases. The acquisition will be executed in two tranches of 19.9% and 20.1%, respectively.

The deal structure involves PharmaDrug issuing a total of 58,807,438 shares, with Canurta receiving approximately 44% ownership of PharmaDrug's outstanding shares. Canurta will contribute $85,000 per tranche through non-interest-bearing promissory notes. Upon first tranche completion, Canurta's CEO Akeem Gardner will join PharmaDrug's Board of Directors.

PharmaDrug (OTC: LMLLF) announced the immediate resignation of Rob Steen from his positions as CEO and board member. Chairman David Kideckel will serve as Executive Chairman and assume the former CEO's responsibilities temporarily. The company, which specializes in controlled substances and natural medicines including psychedelics and previously approved drugs, will begin searching for a new CEO with specific biotech experience. The search will focus on candidates who align with PharmaDrug's strategic direction to streamline its focus on cepharanthine and pharmaceutical drug development.

PharmaDrug Inc. (OTC: LMLLF) has initiated a comprehensive strategic review process led by a newly formed special committee of independent directors to maximize shareholder value. The committee, supported by management, will evaluate the company's current strategy, assets, research programs, and capital structure. The strategic alternatives under consideration include potential asset and business unit sales, management changes, consolidation of Sairiyo Therapeutics, and capital structure modifications. Despite any potential changes, PharmaDrug remains committed to developing Cepharanthine, their key pharmaceutical product.

PharmaDrug has completed the issuance of $412,552.94 in debentures to replace outstanding secured convertible debentures, along with 8,251,058 common share purchase warrants. The new debentures will mature on September 30, 2025, and are convertible into common shares at $0.05 per share. The debentures are secured by a general security agreement and will bear 22% annual interest only if unpaid at maturity. The accompanying warrants allow holders to purchase shares at $0.05 for two years. All securities are subject to a four-month hold period until March 16, 2025.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) announces the issuance of $414,523 in debenture units to replace outstanding secured convertible debentures. The new debentures will mature on September 30, 2025, and are convertible into common shares at $0.05 per share. The company will also issue 8,290,000 common share purchase warrants. No interest will be charged unless principal remains unpaid at maturity, triggering a 22% annual interest rate. The warrants allow holders to purchase shares at $0.05 for two years after issuance.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) has announced the successful completion of a stability study for its patented enteric-coated cepharanthine formulation (PD-001). The six-month accelerated condition study, conducted at 40°C and 75% relative humidity by Genvion , demonstrated acceptable stability parameters for PD-001 in both bottle and encapsulated forms. This achievement supports the manufacturing of clinical trial material for the company's upcoming first-in-human Phase 1 clinical study targeting viral infectious diseases. The study follows the August 2024 approval from the Australian Human Research Ethics Committee to initiate the clinical trial through Sairiyo Therapeutics, which is 51% owned by PharmaDrug and 49% by PharmaTher Holdings.

PharmaDrug Inc. (CSE: PHRX, OTC Pink: LMLLF) has initiated start-up activities for its first clinical study of PD-001, a patented enteric-coated cepharanthine formulation, as a potential treatment for viral infectious diseases. The Phase 1 clinical study, approved by the Australian Human Research Ethics Committee, will assess the bioavailability and pharmacokinetics of PD-001 compared to oral cepharanthine tablets in healthy volunteers.

The study will involve 15 volunteers and last up to 49 days. It aims to demonstrate that PD-001 can achieve better oral pharmacokinetics than generic cepharanthine tablets with similar or improved safety. Upon successful completion, Sairiyo Therapeutics (51% owned by PharmaDrug) plans to seek FDA acceptance for a Phase 2 clinical study in viral infectious diseases.